Edition:
United States

Johnson & Johnson (JNJ)

JNJ on New York Consolidated

119.22USD
27 Sep 2016
Change (% chg)

-- (--)
Prev Close
$119.22
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
6,613,612
52-wk High
$126.07
52-wk Low
$89.90

Select another date:

Mon, Sep 26 2016

Photo

FDA approves J&J's autoimmune drug Stelara for Crohn's disease

Johnson & Johnson said on Monday that the U.S. Food and Drug Administration approved the company's blockbuster psoriasis drug, Stelara, for use in adults with Crohn's disease.

FDA approves J&J's autoimmune drug Stelara for Crohn's disease

Sept 26 Johnson & Johnson said on Monday that the U.S. Food and Drug Administration approved the company's blockbuster psoriasis drug, Stelara, for use in adults with Crohn's disease.

Abbott to sell its eye care business to J&J for about $4.33 billion

Abbott Laboratories said it would sell its eye care business to Johnson & Johnson for about $4.33 billion in cash to focus on cardiovascular devices and diagnostics business.

UPDATE 3-Abbott to sell its eye care business to J&J for about $4.33 bln

Sept 16 Abbott Laboratories said it would sell its eye care business to Johnson & Johnson for about $4.33 billion in cash to focus on cardiovascular devices and diagnostics business.

BRIEF-Abbott to sell Abbott Medical Optics to Johnson & Johnson for $4.325 bln

* Net impact of this transaction is not expected to impact Abbott's overall targeted ongoing earnings per share in 2017.

BRIEF-Johnson & Johnson to buy Abbott Medical Optics for $4.325 bln

* Johnson & Johnson announces agreement to acquire Abbott Medical Optics

Abbott in talks to sell its eye-surgery business to J&J - WSJ

Sept 16 Abbott Laboratories is in talks to sell its eye-surgery business to Johnson & Johnson, the Wall Street Journal reported, citing sources familiar with the matter.

BRIEF-Johnson & Johnson reports 15 pct passive stake in Protagonist Therapeutics - SEC filing

* Johnson & Johnson reports 15.0 pct passive stake in Protagonist Therapeutics Inc as of Aug. 16 Source text (http://bit.ly/2biMrcb) Further company coverage:

BRIEF-Johnson & Johnson announces ruling related to Remicade

* Johnson & Johnson announces ruling related to Remicade in the District of Massachusetts Federal Court hearing

BRIEF-Paulson & Co raises share stake in Valeant, Facebook - SEC filing

* Ups share stake in Valeant Pharmaceuticals International Inc by 43.6 pct to 19.1 mln shares - SEC filing

Select another date: